Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405

Active Not RecruitingPhase 2

Sponsor: Blueprint Medicines Corporation

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Interventions: BLU-808, Placebo

Countries: United States, Denmark, Germany, Italy, Spain, Taiwan

This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Key Inclusion Criteria:

* Part A: Confirmed diagnosis of CIndU for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines.
* Part B: Confirmed diagnosis of CSU for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines.

Key Exclusion Criteria:

* Part A: Any active urticaria that may interfere with study assessments.
* Part B: Participant has a clearly defined predominant cause of chronic urticaria or sole trigger such as symptomatic dermographism and cold-induced urticaria.
* Part A and Part B: Any other skin disease associated with chronic itching or angioedema that might influence the study evaluations and results, skin diseases associated with only wheals and no itch, or autoinflammatory diseases with urticarial lesions.
* Part A and Part B: Significant medical, psychiatric, or surgical conditions, or physical findings that may affect participant safety, study drug metabolism, study participation, or assessment of study results.
* Part A and Part B: Abnormal laboratory values that may pose risks or interfere with study participation.
* Part A and Part B: Pregnancy or plans for pregnancy; breastfeeding.
Locations (47)
  • Birmingham, Alabama, United States
  • Little Rock, Arkansas, United States
  • La Jolla, California, United States
  • Laguna Niguel, California, United States
  • San Diego, California, United States
  • Bradenton, Florida, United States
  • Tampa, Florida, United States
  • Boise, Idaho, United States
  • Northbrook, Illinois, United States
  • Indianapolis, Indiana, United States
  • New Albany, Indiana, United States
  • Plainfield, Indiana, United States
  • Bowling Green, Kentucky, United States
  • Baltimore, Maryland, United States
  • Wheaton, Maryland, United States
  • White Marsh, Maryland, United States
  • Detroit, Michigan, United States
  • Rochester, Minnesota, United States
  • St Louis, Missouri, United States
  • Missoula, Montana, United States
  • New York, New York, United States
  • Cincinnati, Ohio, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Charleston, South Carolina, United States
  • Dallas, Texas, United States
  • Pflugerville, Texas, United States
  • Odense, Denmark
  • Berlin, Germany
  • Dresden, Germany
  • + 17 more on CT.gov